Eligibility focused on p16-negative/HPV-unrelated, PD-L1 ≥1% recurrent/metastatic HNSCC recurring ≥6 months after curative-intent platinum, reflecting a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results